ADUS · Addus HomeCare Corp
$113.27
+0.11 (+0.10%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$2.11B
Shares
18.67M
Volume · Oct 7
229.52K
Avg daily vol (3M)
219.81K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$113.16
Open$114.00
Day$112.24–114.66
52W close$88.49–122.75
Avg vol 30d210K
Short int880K · 4.7% float · 4.5d
Short vol63%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
filed Aug 4, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+0.4%
Trailing year
Short interest
4.7%
Latest settlement · 4.5 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Addus reported 8% revenue growth and 11.9% adjusted EBITDA growth in Q2 2026, with strong cash generation, while a Medicare cap accrual pressured hospice margins and home health same-store revenue continued to decline.
Bullish
- + Q2 revenue rose 8% to $377.4M with adjusted EBITDA up 11.9% to $49.2M and adjusted EPS up 16.1% to $1.73.
- + CMS proposed 2027 home health payment rate increase of 2.1%, reversing last year's 1.3% decrease.
Bearish
- − Home health same-store revenue declined 2.8% year-over-year, though improving from a 6.6% drop in Q1.
- − Q2 gross margin contracted to 32.2% from 32.6% a year ago.
- − Final 2027 hospice rate of 2.3% is 30 bps lower than fiscal 2026's 2.6% increase.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+21%
trailing
YTD return
+5%
this year
Relative strength
+10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $117 › 200d $106 — 50d above 200d
Institutional flow
Distributing
2 of 304 funds reported for Sep 30 · net -1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.71% of float · ▼ -1.7% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
304 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+23%
Y/Y
Gross margin
32%
contracting
EPS growth
+23%
Y/Y
Free cash flow
$103.8M
Valuation
P/E 19.8
in line
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 4, 2026
Adjusted EBITDA margin
· full year
Non-GAAP
12% – 13%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $117 › 200d $106 — 50d above 200d
Institutional flow
Distributing
2 of 304 funds reported for Sep 30 · net -1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.71% of float · ▼ -1.7% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
304 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $88
Now $113 · 72%
Range high $123
vs 200-day avg +7%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADUS
this stock
Addus HomeCare Corp
|
$2.11B | +5.4% | +23.2% | 19.8 | 4.7% |
|
HCA
HCA Healthcare, Inc.
|
$97.43B | -7.4% | +7.1% | 15.1 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.49B | -13.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$11.93B | +17.5% | +10.5% | 19.7 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADUS | +0.2% | -5.2% | +21.3% | +2.4% | +5.4% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -1.8% | -6.9% | +10.0% | +0.2% | -8.9% |